Literature DB >> 22202154

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.

Jostein Dahle1, Nasir Abbas, Øyvind S Bruland, Roy H Larsen.   

Abstract

Radioimmunotherapy based on α-particle emitters has excellent properties as a treatment against micrometastatic and disseminated cancers because of the short path length (50 - 80 μm) and high linear energy transfer (∼ 100 keV/ μm). Alpha-particles produce clustered DNA double-strand breaks and highly reactive hydroxyl radicals when hitting biological tissue. Hence, targeted α-particle therapy offers the potential of selective tumor cell killing with low damage to surrounding normal tissue. The ideal applications for targeted α-therapy are in treating neoplastic cells in circulation or when cancer cells are present as free-floating cells or spread along compartment walls. This review will provide a brief overview of the most promising radionuclides for targeted α-therapy and compare their relative biological effectiveness (RBE) and normal tissue toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202154     DOI: 10.2174/1874471011104040321

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  11 in total

1.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

3.  Effect of densely ionizing radiation on cardiomyocyte differentiation from human-induced pluripotent stem cells.

Authors:  Erdene Baljinnyam; Sundararajan Venkatesh; Richard Gordan; Satvik Mareedu; Jianyi Zhang; Lai-Hua Xie; Edouard I Azzam; Carolyn K Suzuki; Diego Fraidenraich
Journal:  Physiol Rep       Date:  2017-08

4.  In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.

Authors:  Vilde Y Stenberg; Asta Juzeniene; Øyvind S Bruland; Roy H Larsen
Journal:  Curr Radiopharm       Date:  2020

5.  The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study.

Authors:  Rosa Sciuto; Sandra Rea; Sara Ungania; Antonella Testa; Valentina Dini; Maria Antonella Tabocchini; Clarice Patrono; Antonella Soriani; Valentina Palma; Raffaella Marconi; Lidia Strigari
Journal:  J Exp Clin Cancer Res       Date:  2021-09-06

6.  Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).

Authors:  Naoyuki Ukon; Tatsuya Higashi; Makoto Hosono; Seigo Kinuya; Takahiro Yamada; Sachiko Yanagida; Masao Namba; Yoshihide Nakamura
Journal:  Ann Nucl Med       Date:  2022-07-06       Impact factor: 2.258

7.  Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.

Authors:  Sophie E Eriksson; Tom Bäck; Erika Elgström; Holger Jensen; Rune Nilsson; Sture Lindegren; Jan Tennvall
Journal:  EJNMMI Res       Date:  2013-04-04       Impact factor: 3.138

8.  Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.

Authors:  Vincent Boudousq; Laure Bobyk; Muriel Busson; Véronique Garambois; Marta Jarlier; Paraskevi Charalambatou; André Pèlegrin; Salomé Paillas; Nicolas Chouin; François Quenet; Patrick Maquaire; Julien Torgue; Isabelle Navarro-Teulon; Jean-Pierre Pouget
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

9.  Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [211At] NaAt in Mice: A Revisit.

Authors:  Yuwei Liu; Tadashi Watabe; Kazuko Kaneda-Nakashima; Kazuhiro Ooe; Yoshifumi Shirakami; Atsushi Toyoshima; Eku Shimosegawa; Takashi Nakano; Atsushi Shinohara; Jun Hatazawa
Journal:  Transl Oncol       Date:  2020-03-25       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.